independently. To our knowledge these small series have not been expanded and in at least one of them no new% remission has been obtained. '8 We did not expect to obtain remissions from L-dopa because it is a poor inhibitor of prolactin secretion. Rozencweig et al.1' showed that L-dopa produced a saw-tooth effect on blood prolactin levels, with decreases followed by large rebounds. 
reviewed independently. To our knowledge these small series have not been expanded and in at least one of them no new% remission has been obtained. '8 We did not expect to obtain remissions from L-dopa because it is a poor inhibitor of prolactin secretion. Rozencweig et al. 1' showed that L-dopa produced a saw-tooth effect on blood prolactin levels, with decreases followed by large rebounds. Bromocriptine (CB 154), however, steadily depressed the blood prolactin level down to 250% of the pretreatment level in postmenopausal women.'0 Yet bromocriptine also failed tc produce a single case of remission of breast cancer.' 9 If prolactin suppression were therapeutically effective in breast cancer favourable results would be expected from bromocriptine rather than from L-dopa. Indeed, if convincing evidence should be produced showing breast cancer regression under L-dopa treatment other mechanisms than prolactin suppression should be looked for.
Do the negative results with L-dopa and bromocriptine rule out any influence of endogenous prolactin on the maintenance of breast cancer growth ? Extreme caution is needed in answering this question because none of these drugs can suppress totally the blood prolactin.' 0 For a definitive answer more potent drugs must become available. Obviously, these results do not exclude the possibility that prolactin might be a key factor in breast carcinogenesis or very early stages of breast cancer development, as suggested by observations in animal models and by the recent report of Kwa et al. 5 Introduction Severe asthma, refractory to previous bronchodilator treatment, placebo pressurized aerosol (2 puffs). All treatments were made up to 100 ml with Soo dextrose injection B.P.
Ventilatory response was determined by measuring the FEV, with a dry spirometer (Vitalograph). The heart rate was taken from lead 2 of an E.C.G. and blood pressure with a mercury sphygmomanometer. Digital skeletal muscular tremor was measured 13 As an expression of the total effect of each drug the areas (FEV, (table III) . Only the area for high-dose rimiterol was significantly greater than high-dose salbutamol during all infusion periods (P<0 05).
CARDIOVASCULAR STUDIES
The mean rise in heart rate with rimiterol infusions was significantly greater than the change after placebo from 30 minutes (P<0 05), 10 minutes (P<0-02), and 5 minutes (P<0-01) with the low, medium, and high doses respectively, and all the mean peak increases occurred at 45 minutes ( fig. 3 ). The tachycardia with each dose seemed to level out after 30 minutes though there was a significant difference between the heart rate increase at 10 and 60 minutes after the high dose (P<0 05). During salbutamol infusions significant mean heart rate rises compared to the change after placebo occurred from 45 minutes, (P <0 05), 5 minutes (P <0 02), and 10 minutes (P <001) for the low, medium, and high doses respectively (fig. 4) . The mean peak heart rate increases with salbutamol were observed at 10 minutes with low dose and 60 minutes with medium and high doses. With salbutamol medium and high doses the heart rate was still rising at 60 minutes and was significantly higher than at 10 minutes (P<0-01). After the appropriate aerosol inhalations the heart rate declined, and at 30 minutes only high-dose rimiterol (P<0 05) and medium-dose (P<0-02) and high-dose (P<0 05) salbutamol produced a significant increase compared with placebo. Similarly with salbutamol some mean increases were significantly greater than the change after placebo for both infusion periods (medium dose P<0-02, high dose P<0-01) and for the postinfusion period (high dose P<0-01). There were no significant differences in pressure between the corresponding doses of each drug for any period. 
Discussion
Studies with single equimolar intravenous injections of isoprenaline, salbutamol, and rimiterol in healthy people with histamine-induced bronchoconstriction"3 and asthmatic patients14 have shown that for equal bronchodilatation isoprenaline increased the heart rate two and two and a half times more, respectively, than rimiterol and salbutamol. The duration of action of rimiterol is short, which confirms that it has a short half life like that of isoprenaline"5and unlike that of salbutamol.18
Effective bronchodilatation with rimiterol and salbutamol was accompanied by heart rate increases of greater than 20 beats/min. Of the p-adrenoceptor stimulating drugs only isoprenaline has been described for intravenous therapy in severe asthma,2 and relatively good tolerance to the tachycardias produced by large doses was shown in children when adequate oxygenation was ensured. It is desirable, however, that bronchodilator treatment should produce minimal cardiac stimulation, so we assessed the effects of rimiterol and salbutamol-selective N3-adrenoceptor stimulating drugs-in asthmatic patients by constant low dose intravenous infusions. The three doses of each drug were selected according to the results of previous studies." 3 14 Both drugs produced and maintained effective dose-related bronchodilatation during the one-hour intravenous infusions. Because of its short half life rimiterol produced peak bronchodilatation within the hour, but salbutamol might need longer for its full respiratory effect to be manifest. We assessed the possibility of the development of resistance because of prolonged sympathetic stimulation by the response to the prescribed dose of each drug by pressurized aerosol at the end of each infusion. Rebound bronchoconstriction has been observed during bronchodilator trials,7 1314 2324 and patients have become refractory to excessive doses of adrenergic drugs until their withdrawal.' ''7 Metabolites of 57-adrenoceptor agonists with weak p-adrenoceptor antagonistic properties28 29 and resistance to the natural adrenergic transmitter30 have been suggested as possible causes of these phenomena. Studies in animals3" and man32"35 have failed to confirm resistance to the respiratory effects of P-adrenoceptor agonists. We found no evidence of bronchial resistance resulting from the one-hour infusions. A similar FEV, increase after the drug aerosol inhalations, until the patients reached near-maximal bronchodilatation, was observed regardless of the dose of the preceding infusion. It should be emphasized that patients with severe asthma might initially be more refractory to this treatment than our patients, who were very responsive though they often showed the need for treatment at the start of a study because of increasing wheeze and dyspnoea.
The heart rate reached equilibrium earlier during rimiterol infusions and declined more rapidly after they had stopped, which showed its shorter duration of action. A longer infusion time is needed to determine the maximal heart rate attainable with salbutamol. There was great individual variation in the peak heart rate increases, ranging from 12 to 30 beats/min with the high doses but always less than 10 beats/min with the low doses of each drug. These results indicate that in an individual patient effective bronchodilatation may be produced with minimal heart rate increases.
The dose-related increases in pulse pressure with the lower doses of each drug were unlikely to be significant, though their effects on pulsus paradoxus, which often occurs in severe asthma,5 are unknown. We saw no evidence of cardiovasulcar resistance during the drug infusions. Cardiovascular resistance to prolonged sympathetic stimulation by 3-adrenoceptor agonists has been observed in animals30 36-38 and man,28 30 but other workers have failed to show such resistance.33 39 Both the individual control amplitude of tremor and the post-treatment increases were variable. Also, during the infusions the level of tremor varied, but with all doses the symptoms were generally minimal and unlikely to be troublesome with the thwrapeutic doses envisaged.
Constant intravenous infusions provide predictable drug concentrations in the blood and at the receptor sites. When the drug has a short half life blood concentration equilibrium will be reached rapidly and maintained precisely by a constant infusion enabling accurate monitoring. Woolcock and Read40
have shown that FEV, may be an unreliable guide in assessing early improvement in patients with severe asthma associated with marked lung hyperinflation. Thus, the drug dose should be monitored by the heart rate change in the individual patient. Cooke et al. 41 have shown that the tachycardia after rimiterol administered by I.P.P.V. was less in magnitude and duration than after salbutamol and suggested that rimiterol may become the bronchodilator of choice for I.P.P.V. treatment in asthma. Further studies are in progress to assess rimiterol intravenous infusions over longer periods with particular reference to selectivity and resistance. If our findings are confirmed rimiterol may prove to be a valuable bronchodilator for intravenous treatment in severe asthma either alone or in combination with rimiterol by I.P.P.V.
Introduction
The separation of heredity and enviromment in the determination of body fat has proved difficult for want of suitable material and sufficient data. The use of weight alone to measure fatness in humans is uninformative, and weight-for-height indices do little to improve the information because of the large differences in body proportions between people of the same height and sex. Skinfold thicknesses correlate well with total body fat in both adults' and children. 2 One study of monozygotic twins brought up together and apart depended only on measurement of weight.3 Another reported parent/child correlation coefficients of weight and skinfold thickness in children up to the age of 7 years; for weight Unit a higher correlation was found for mother/child than for father/ child but for skinfold thickness the correlation coefficients were not significantly different from zero.4 On the other hand the correlations of skinfold thickness in adult twins suggested that genetic influences were strong but that the influence of sex, heredity, and environment differed for different sites. 5 We report here the relative contribution of genetic and environmental factors to the variation of skinfold thickness in children of both sexes aged 3-15 years.
Patients and Methods
All twins registered at the Hospital for Sick Children, Great Ormond Street, aged 3-15 years who livcd in Greater London were invited to take part. More twins were obtained through an appeal for volunteers at the end of a television programme about twins. 6 Skinfold thicknesses were measured in the standard manner using a Harpenden skinfold caliper7 over the mid-point of the triceps muscle on the left arm (representative of limb fat) and under the angle of the left scapula (representative of trunk fat). Since skinfold thicknesses are distributed logarithmically in man,8 log-transformed scores were used throughout. During childhood the means and standard deviations of skinfold thickness change with age and sex; thus departures from the mean assume different importance at different ages, and standard deviation scores9 were therefore calculated in all cases using standard control values for each age and sex.'0 Heritability, defined as the proportion of total variance of a characteristic in a particular population due to genetic causes, was calculated by three different methods from the correlation coefficients of skinfold thicknesses. If the variation of a characteristic is entirely genetically determined the correlation coefficient in monozygotic twins, who have all their genes in common, would be 1-0. In dizygotic twins, who have half their genes in common, the expected correlation coefficient would be 0 5. Accordingly, the estimate of heritability is given by the correlation coefficient in monozygotic twins (rMZ), twice the correlation coefficient in dizygotic twins (2rDZ), or twice the difference between the correlation coefficients in monozygotic and dizygotic twins 
